| At Rome Therapeutics, Kapeller Aims to Turn “Junk” Into New Drugs | Sarah de Crescenzo | 04/28/20 | Boston |
| Erasca Lands $200M Mega-Round to Move Cancer Programs to the Clinic | Sarah de Crescenzo | 04/27/20 | San Diego |
| Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More | Frank Vinluan | 04/24/20 | National |
| Life Science a VC Bright Spot in Q1, But Startups May Soon Struggle | Sarah de Crescenzo | 04/23/20 | National |
| Eureka Partners With Lyell to Tackle Tricky Solid Tumor Cell Therapies | Sarah de Crescenzo | 03/20/20 | San Francisco |
| How San Diego Biotech Leaders Are Adapting to Coronavirus Concerns | Sarah de Crescenzo | 03/19/20 | San Diego |
| Amunix Raises $73M to Bring Safer T Cell Engagers to Solid Tumors | Sarah de Crescenzo | 03/04/20 | San Francisco |
| ORIC Pharma Plans IPO to Test Therapies for Drug-Resistant Cancers | Sarah de Crescenzo | 03/02/20 | San Francisco |
| Bio Roundup: Agile Approval, Coronavirus Collabs, Spruce’s $88M & More | Sarah de Crescenzo | 02/21/20 | National |
| Bio Roundup: POTUS on Prices, a16z’s Fund, Aimmune’s Approval & More | Sarah de Crescenzo | 02/07/20 | National |
| $750M Fund Looks to Software Sector to Drive Future of Biotech | Sarah de Crescenzo | 02/04/20 | National |
| Vizgen Launches With $14M to Market New Subcellular Imaging Technique | Sarah de Crescenzo | 01/30/20 | Boston |
| Life Sciences IPOs Target Collective Raise of More Than $600M This Week | Sarah de Crescenzo | 01/27/20 | National |
| Bio Roundup: Coronavirus Concerns, Sarepta’s CRL, Eye Drug OK’d & More | Sarah de Crescenzo | 01/24/20 | National |
| CEOs of Women’s Health Companies Fight to Open Investment Floodgates | Sarah de Crescenzo | 01/22/20 | San Diego |
| DTx Pharma Raises $10.6M to Advance New Way to Deliver RNA Drugs | Sarah de Crescenzo | 01/09/20 | San Diego |
| Empirico Raises $17M, Inks 3-Year Antisense Collaboration with Ionis | Sarah de Crescenzo | 01/09/20 | San Diego |
| Investors Go With Gut Ahead of Microbiome Therapy Boom, Says Seventure | Dan Stanton | 01/01/20 | National |
| Flagship’s Cellarity Aims to Advance Cell Behavior-Based Therapeutics | Sarah de Crescenzo | 12/11/19 | Boston |
| Bio Roundup: Biogen at CTAD, Sage’s Stumble, Astellas’s $3B Offer & More | Sarah de Crescenzo | 12/06/19 | National |
| Digital Health Survivors & Innovative Incumbents Must Team Up for True Disruption | Bryony Winn | 12/04/19 | Raleigh Durham |
| Partner or Die: How to Succeed Even After the Digital Health Hype Quiets Down | Rob Coppedge | 12/03/19 | Seattle |
| Biotech VC Down 20% in US as Policies Drive Away Foreign Investors, BIO Says | Dan Stanton | 11/29/19 | National |
| Five Questions With a16z’s Vijay Pande on AI and Making New Drugs | Sarah de Crescenzo | 11/25/19 | National |
| Biopharma Execs Remain Optimistic Despite Political Headwinds | Mike Ward | 11/20/19 | National |
| AI Can Unlock Health Data’s Potential, But Access Is Still Difficult | Jeff Bauter Engel | 11/07/19 | Wisconsin |
| Venture Investors Bets on Healthcare, and Milwaukee, With $75M Fund | Jeff Bauter Engel | 10/28/19 | Wisconsin |
| Healx Bags $56M to Advance Affordable, AI-Based Orphan Drugs | Mike Ward | 10/17/19 | National |
| WI Watchlist: Epic, Shine, Venture Investors, Stratatech & More | Jeff Bauter Engel | 10/09/19 | Wisconsin |
| Unpack Digital Health’s Progress & Pitfalls at X·CON on Oct. 22 | Jeff Bauter Engel | 10/07/19 | Boston |
